+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 622 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are studying patients with low-risk intermediate-stage nasopharyngeal carcinoma who have responded well to induction chemotherapy and have undetectable levels of plasma EBV-DNA. The trial compares two doses of radiotherapy targeting a specific low-risk area to evaluate their effects on survival, side effects, and quality of life. This phase 3 randomized study aims to find out if lower-dose radiotherapy can maintain treatment success while reducing toxicities related to treatment. Participants receive either reduced-dose radiotherapy 40.2Gy or conventional-dose radiotherapy 49.2Gy to the low-risk target volume called CTV2. Both groups undergo full-course immunotherapy with the PD-1 monoclonal antibody Tislelizumab, administered every three weeks, totaling 12 courses through induction, radiotherapy, and maintenance phases. Induction chemotherapy using a cisplatin-based regimen is given before radiotherapy. Treatment continues until toxicity, progression, withdrawal, or completion of planned courses. During the study, patients will be monitored for progression-free survival and serious adverse events over three years. Secondary measures include metastasis-free survival, relapse-free survival, overall survival, tumor response rates, and quality of life assessments using standard questionnaires over three years. Safety and effectiveness will be evaluated through imaging, laboratory tests, and clinical evaluations. The study enrollment includes adults aged 18 to 75 years, and the follow-up will provide information on long-term outcomes and treatment impact.

Age: 18Years - 75YearsAll GendersPhase 3
15 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and diagnostic effectiveness of 18FFT8 PET imaging for detecting AL amyloidosis, focusing on its ability to directly visualize amyloid deposits in heart tissue. The study compares this new imaging approach with established methods such as echocardiography, contrast-enhanced MRI, and various laboratory tests to better differentiate AL amyloidosis from other conditions. Participants will receive a single intravenous injection of 10 3 mCi of 18FFT8, followed by a PETCT scan to assess organ uptake using standardized uptake values SUV. The study includes both patients with suspected or diagnosed cardiac amyloidosis and healthy volunteers. Clinical assessments and laboratory tests, including physical exams and evaluations of cardiac, liver, and kidney function, will be done before and after the scan to monitor safety and biodistribution. During the study, participants will undergo a single PETCT scan session and related clinical evaluations. Researchers will monitor safety from the time of injection up to seven days afterward and analyze the radiation dosage and biodistribution of 18FFT8. The total participation involves initial assessments, the scan, and follow-up safety monitoring, with data collected primarily on the imaging results and participant well-being.

Age: 18Years +All Genders
3 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying a new imaging tracer called 18FNIDF to detect abnormal tau protein buildup in the brains of people with neurodegenerative diseases, including Alzheimers disease and related tauopathies. This study focuses on evaluating the safety and diagnostic ability of 18FNIDF PET imaging in living human brains, aiming to improve visualization of tau pathology compared to existing tracers. The research is sponsored by Tianjin Medical University. Participants receive a single intravenous injection of about 10 3 mCi of 18FNIDF, followed by a PETCT scan to track the tracers distribution in the brain. The study includes both healthy volunteers and patients with cognitive impairments, such as probable Alzheimers disease or other dementias. The imaging is done once, and safety is monitored up to 7 days after injection. During the study, participants will be observed for any side effects and undergo a PETCT scan to assess how well the tracer binds to tau proteins. Researchers will measure safety from the time of injection up to one week later and evaluate the diagnostic performance within two weeks of scanning. The total participation period includes the imaging day and follow-up safety assessments, with the study running until December 2030.

Age: 18Years - 90YearsAll Genders
3 locations
P

Actively Recruiting

Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.

Age: 18Years - 80YearsAll GendersPhase 3
38 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.

Age: 18Years +All GendersPhase 2Phase 3
51 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are studying cizutamig in patients with thyroid eye disease TED to evaluate its safety, tolerability, how the body processes the drug pharmacokinetics, its effects on the body pharmacodynamics, immune response, and preliminary clinical activity. This Phase 1b, open-label, multicenter trial focuses on patients diagnosed with Graves Disease who have active, moderate to severe TED. Participants will receive cizutamig dosed according to the study protocol. The study does not include a placebo group, and all participants receive the experimental drug. The trial aims to observe the bodys reaction to cizutamig and collect detailed data on drug levels and immune responses throughout treatment. During the study, participants will be monitored for adverse events and changes in vital signs such as body temperature, heart rate, respiratory rate, blood pressure, and pulse oximetry. Electrocardiogram ECG parameters and laboratory safety tests including serum chemistry and blood counts will also be assessed from baseline through 12 months. The research team will track pharmacokinetic parameters including peak concentration, clearance, and half-life of the drug. Participants will attend regular visits for assessments and safety monitoring over the course of one year.

Age: 18Years - 75YearsAll GendersPhase 1
14 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of QT-019B, a dual-target, universal CAR-T cell therapy for adults with refractory systemic lupus erythematosus SLE. This phase IIIa clinical study aims to determine the recommended dose RD and understand how the treatment affects disease activity in patients who have not responded to standard therapies. The study is sponsored by Hangzhou Qihan Biotech Co., Ltd. and plans to enroll between 18 and 24 participants. The study consists of two main phases dose escalation and dose expansion. Initially, participants receive a QT-019B cell injection at Dose A 1106kg, with a 14-day interval between enrollments. If no dose-limiting toxicities DLTs are observed during the observation period, the study may proceed to Dose B 3106kg. If DLTs occur, additional participants may be enrolled at Dose A, or the study dose may be reduced or the study terminated depending on the number of DLTs observed. Participants will be closely monitored through safety assessments including tracking adverse events within 28 days of treatment. Researchers will also evaluate changes in disease activity scores such as the SLEDAI-2000, Physicians Global Assessment, and BILAG-2004 Index over up to two years. Blood samples will be collected to measure the concentration and behavior of QT-019B cells. The overall study involves regular visits, assessments, and follow-up to comprehensively evaluate safety and treatment impact over time.

Age: 18Years - 65YearsAll GendersPhase 1
3 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and preliminary effectiveness of GO306 Recombinant Oncolytic Vaccinia Virus Injection in patients with advanced solid tumors who have not responded to standard treatments. This open-label, non-randomized trial uses a dose-escalation design to explore the best dose and safety profile. The trial has two parts first to find the maximum tolerated dose and then to evaluate repeated doses in specific tumor types. The study involves two phases Part 1 uses a 33 design with single intratumoral or intracavitary injections of GO306 at low, medium, and high doses to determine the recommended dose for further study. Part 2 involves multiple doses of GO306 given weekly or every two weeks at the recommended dose to evaluate safety and explore preliminary effectiveness in selected tumor types. Participants will receive treatment injections and undergo monitoring for side effects, pharmacokinetics, viral shedding, and immune response. Researchers will assess adverse events, dose-limiting toxicities, and treatment responses using imaging. Follow-up evaluations include laboratory tests and immunological assessments. Study participation may last months, with some outcomes monitored up to five years after treatment.

Age: 18Years +All GendersPhase 1
6 locations

1-10 of 622

1